{"product_id":"9781394281619","title":"Crystallization of Active Pharmaceutical Ingredients: Practical Approaches, Advances, and Trends","description":"\u003ch1\u003eCrystallization of Active Pharmaceutical Ingredients: Practical Approaches, Advances, and Trends\u003c\/h1\u003e \u003ch2\u003eDerdour, Lotfi\u003c\/h2\u003e \u003cp\u003e\u003c\/p\u003e\u003cp\u003e\u003cb\u003eNavigate evolving API crystallization challenges driven by changing molecular properties\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003eThe continuous drive to develop drugs with improved efficacy and safety had resulted in changes in molecular descriptors of drug candidates in the last two decades. An increasing number of drug candidates with higher molecular weight, increased lipophilicity, greater restricted flexibility, are transitioning from drug discovery to drug development. This shift in molecular descriptor has been correlated with  declining solubility and crystallization tendency. \u003ci\u003eCrystallization of Active Pharmaceutical Ingredients: Practical Approaches, Advances, and Trends\u003c\/i\u003e addresses these emerging difficulties, providing strategies that align crystallization objectives with evolving drug development phases while targeting growing ambitious sustainability objectives, and managing drug attrition risks and development costs. \u003c\/p\u003e\u003cp\u003eThe book examines evolving complex polymorphic landscape assessment and solid form selection, growing occurrence of oiling out and gelation phenomena, declining solubility-related obstacles, purification by solution crystallization, and reviews emerging particle formation technologies including crystallization of large biomolecules. Coverage extends to process sustainability goals targeting waste and carbon footprint reduction, digital transformation through modeling and simulation, and strategic resourcing through alliances and partnerships. \u003c\/p\u003e\u003cp\u003eKey topics also include: \u003c\/p\u003e\u003cul\u003e \u003cli\u003eCrystallization process design, scale-up, and scale-down methodologies applicable across pharmaceutical, fine chemical, and energy storage operations\u003c\/li\u003e \u003cli\u003eHow increasing process sustainability requirements create additional constraints on crystallization development workflows and solvent selection decisions\u003c\/li\u003e \u003cli\u003eEvolution of crystallization deliverables across drug development phases to balance quality attributes against attrition risk and cost\u003c\/li\u003e \u003cli\u003eStrategic business considerations such as externalization, in-licensing, and partnership models for drug substance crystallization resourcing\u003c\/li\u003e \u003cli\u003eProjected future trends in API particle formation processes, technologies, materials, and operational approaches\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eDesigned for chemical engineers and chemists involved in development, scale-up, or operation of crystallization processes in pharmaceutical, fine chemical, and energy storage industries, this book connects current trends in molecular properties to recent challenges to crystallization development, and reviews approaches and strategies published in recent literature to t address those challenges from both technical and business dimensions of drug substance development.\u003c\/p\u003e \u003ch3\u003eDetails\u003c\/h3\u003e \u003cp\u003ePublished by: Wiley\u003c\/p\u003e \u003cp\u003ePublication Date: 2026-12-30\u003c\/p\u003e \u003cp\u003eFormat: Hardcover\u003c\/p\u003e \u003cp\u003eISBN-13: 9781394281619\u003c\/p\u003e \u003cp\u003eDOI: \u003c\/p\u003e \u003cp\u003eDimensions: cm xcm\u003c\/p\u003e \u003cp\u003ePages: 800\u003c\/p\u003e ","brand":"Wiley","offers":[{"title":"Default Title","offer_id":49600806944908,"sku":"9781394281619","price":175.5,"currency_code":"USD","in_stock":true}],"url":"https:\/\/fh90cf-fv.myshopify.com\/products\/9781394281619","provider":"Late Knight Books and Services, LLC","version":"1.0","type":"link"}